Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


14 enero 2013

Estudio detecta aumento de hígados para trasplantes sin utilizar en EEUU

Reuters Health

La cantidad de hígados de donante que se desperdician en Estados Unidos creció desde el 2004, en parte debido al envejecimiento y la obesidad de la población, según revela un estudio que muestra también los cambios de la práctica médica que reducirían la viabilidad de algunos donantes.

31 diciembre 2012

Paired CT Scans Catch Chemo-Killing of Liver Tumors in Real Time

Science Daily

Using two successive pairs of specialized CT scans, a team of Johns Hopkins and Dutch radiologists has produced real-time images of liver tumors dying from direct injection of anticancer drugs into the tumors and their surrounding blood vessels. Within a minute, the images showed whether the targeted chemotherapy did or did not choke off the tumors blood supply and saved patients a month of worry about whether the treatment, known as chemoembolization, was working or not, and whether repeat or more powerful treatments were needed.

23 enero 2013

Associations Look to Magazines to Enhance Membership Experience

Audience

In an effort to better serve their members, two associations are jumping into the magazine publishing business—the Society of Interventional Radiology (SIR) and the National Association of Home Builders (NAHB) have each launched new magazines to better communicate critical information and industry updates to their core groups.

EDAP Submits U.S. FDA Pre-Market Approval Application for Ablatherm(R)-HIFU for Treatment of Low Risk, Localized Prostate Cancer

20130202

EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, announced today the submission of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) on January 31, 2013 for the Company s Ablatherm-HIFU (High Intensity Focused Ultrasound) for treatment of low risk, localized prostate cancer. EDAP s PMA submission includes data from the ENLIGHT study, a multi-center U.S. Phase II/III clinical trial that completed the two year follow-up needed to evaluate its primary endpoint in August 2012, as well as data from the Company s extensive worldwide database of treatment information and follow-up data from patients who have undergone HIFU therapy for prostate cancer

14 enero 2013

Indian stent makers target international markets

Fierce Medical Devices

Indian stent makers are becoming increasingly viable competitors in international markets, adding another layer to an industry already crowded with a number of players.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.